Posters
The effects of orthokeratology for myopia control in Jakarta Eye Center, Jakarta, Indonesia
Poster Details
First Author: A.Pertiwi INDONESIA
Co Author(s): T. Rahayu
Abstract Details
Purpose:
Orthokeratology (ortho-k) is a clinical technique that uses specially designed rigid gas permeable (RGP) contact lenses to reshape corneal contour during sleep in order to temporarily reduce or eliminate refractive error. The aim of this study was to evaluate the effectiveness of overnight ortho-k lens wear for treatment of myopia and to evaluate possible corneal changes during the treatment.
Setting:
This study was conducted in Jakarta Eye Center (JEC) Eye Hospital Kedoya, Jakarta, evaluating the data of patients who underwent orthokeratology treatment from 2016 to 2017.
Methods:
Twenty-three low to moderate myopic patients (46 eyes) fitted with ortho-k lenses were evaluated retrospectively. Data collection including uncorrected visual acuity (UCVA), spherical equivalent (SE), and parameters of corneal topography (keratometry = Kmean; pachymetry = pupil pachy, apical pachy) were performed at baseline and 1 day, 1 week, 1 month, and 3 months after the commencement of lens wear. Data of biometric characteristic and lens parameter measured before lens fitting were also evaluated.
Results:
Before lens fitting, subjects had baseline mean UCVA of 0.083±0.096 (decimal value) and mean SE of 3.96±1.32 diopters (D). At 1 day, 1 week, 1 month, and 3 months of treatment, mean UCVAs were 0.28±0.27, 0.72±0.32, 0.86±0.23, and 0.87±0.12; and mean SE were 2.70±1.65, 0.83±1.02, 0.43±0.68, and 0.27±0.33 D respectively. Subjects showed such a good response after 1 week of treatment, that UCVA improved and SE reduced significantly (p=0.022 and p=0.020). Meanwhile, significant decrease in Kmean and pupil pachy were found after 1 month of treatment (p<0.001 and p=0.028).
Conclusions:
Overnight ortho-k lens wear was safe and effective as non-surgical approach for those who had low to moderate myopia and wanted to be glasses and contact lens-free.
Financial Disclosure:
None